{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T16:20:57Z","timestamp":1778516457883,"version":"3.51.4"},"reference-count":57,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1097\/iae.0000000000000253","type":"journal-article","created":{"date-parts":[[2014,8,6]],"date-time":"2014-08-06T10:59:42Z","timestamp":1407322782000},"page":"1719-1727","source":"Crossref","is-referenced-by-count":45,"title":["OCULAR PHARMACOLOGY OF TOPOTECAN AND ITS ACTIVITY IN RETINOBLASTOMA"],"prefix":"10.1097","volume":"34","author":[{"given":"Paula","family":"Schaiquevich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angel M.","family":"Carcaboso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emiliano","family":"Buitrago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Taich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Opezzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Bramuglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo L.","family":"Chantada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-1-20210130","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1136\/bjo.2009.168062","article-title":". Survival of retinoblastoma in less-developed countries impact of socioeconomic and health-related indicators.","volume":"94","author":"Canturk","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"R2-1-20210130","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1001\/archopht.1996.01100140539004","article-title":". Results of combined chemotherapy and radiotherapy for advanced intraocular retinoblastoma.","volume":"114","author":"Kingston","year":"1996","journal-title":"Arch Ophthalmol"},{"key":"R3-1-20210130","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/ICU.0b013e328338676a","article-title":"Retinoblastoma management: advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy.","volume":"21","author":"Shields","year":"2010","journal-title":"Curr Opin Ophthalmol"},{"key":"R5-1-20210130","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/bmt.2008.181","article-title":". Tandem high-dose chemotherapy and autologous stem cell rescue in children with bilateral advanced retinoblastoma.","volume":"42","author":"Lee","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"R6-1-20210130","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s11095-008-9694-0","article-title":". Recent perspectives in ocular drug delivery.","volume":"26","author":"Gaudana","year":"2009","journal-title":"Pharm Res"},{"key":"R7-1-20210130","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1200\/JCO.1995.13.4.902","article-title":". Etoposide and carboplatin in extraocular retinoblastoma: a study by the Societe Francaise dOncologie Pediatrique.","volume":"13","author":"Doz","year":"1995","journal-title":"J Clin Oncol"},{"key":"R8-1-20210130","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1200\/JCO.1999.17.6.1847","article-title":". Phase II window of idarubicin in children with extraocular retinoblastoma.","volume":"17","author":"Chantada","year":"1999","journal-title":"J Clin Oncol"},{"key":"R10-1-20210130","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1002\/1097-0142(20011201)92:11<2933::AID-CNCR10071>3.0.CO;2-G","article-title":". Histopathologic features of retinoblastoma and its relation with in vitro drug resistance measured by means of the MTT assay.","volume":"92","author":"Schouten-van Meeteren","year":"2001","journal-title":"Cancer"},{"key":"R11-1-20210130","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0003-2697(03)00349-X","article-title":". High-throughput screening for the identification of small-molecule inhibitors of retinoblastoma protein phosphorylation in cells.","volume":"320","author":"Barrie","year":"2003","journal-title":"Anal Biochem"},{"key":"R12-1-20210130","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11010-009-0077-6","article-title":". Characterization of the ATP-binding cassette transporter gene expression profile in Y79: a retinoblastoma cell line.","volume":"328","author":"Hendig","year":"2009","journal-title":"Mol Cell Biochem"},{"key":"R13-1-20210130","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1167\/iovs.06-0796","article-title":". Paclitaxel in the treatment of retinal tumors of LH beta-Tag murine transgenic model of retinoblastoma.","volume":"48","author":"Suarez","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R14-1-20210130","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1167\/iovs.11-8265","article-title":". Retinoblastoma treatment: utilization of the glycolytic inhibitor, 2-deoxy-2-fluoro-D-glucose (2-FG), to target the chemoresistant hypoxic regions in LH(BETA)T(AG) retinal tumors.","volume":"53","author":"Pina","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R15-1-20210130","doi-asserted-by":"crossref","first-page":"e332","DOI":"10.1371\/journal.pmed.0020332","article-title":"Use of preclinical models to improve treatment of retinoblastoma.","volume":"2","author":"Dyer","year":"2005","journal-title":"PLos Med"},{"key":"R16-1-20210130","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1001\/archopht.120.4.460","article-title":". Factors predictive of recurrence of retinal tumors, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma.","volume":"120","author":"Shields","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"R17-1-20210130","doi-asserted-by":"crossref","first-page":"5885","DOI":"10.1158\/0008-5472.CAN-09-0700","article-title":". Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid.","volume":"69","author":"Shen","year":"2009","journal-title":"Cancer Res"},{"key":"R18-1-20210130","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1200\/JCO.2003.04.053","article-title":". Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis.","volume":"21","author":"Blaney","year":"2003","journal-title":"J Clin Oncol"},{"key":"R19-1-20210130","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/13816810902988780","article-title":". Retinoblastoma CSF metastasis cured by multimodality chemotherapy without radiation.","volume":"30","author":"Dimaras","year":"2009","journal-title":"Ophthalmic Genet"},{"key":"R20-1-20210130","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00043426-199807000-00006","article-title":". Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group Phase II Study.","volume":"20","author":"Nitschke","year":"1998","journal-title":"J Pediatr Hematol Oncol"},{"key":"R21-1-20210130","first-page":"3956","article-title":". Phase I study of topotecan administered as a 21-day continous infusion in children with recurrent solid tumors: a report from the Childrens Cancer Group.","volume":"5","author":"Frangoul","year":"1999","journal-title":"Clin Cancer Res"},{"key":"R22-1-20210130","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1076\/opge.25.1.37.28996","article-title":". Activity of topotecan in retinoblastoma.","volume":"25","author":"Chantada","year":"2004","journal-title":"Ophthalmic Genet"},{"key":"R23-1-20210130","doi-asserted-by":"crossref","first-page":"7569","DOI":"10.1158\/1078-0432.CCR-05-0849","article-title":". Topotecan combination chemotherapy in two new rodent models of retinoblastoma.","volume":"11","author":"Laurie","year":"2005","journal-title":"Clin Cancer Res"},{"key":"R24-1-20210130","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2002.20.1.88","article-title":". Phase I study of combination topotecan and carboplatin in pediatric solid tumors.","volume":"20","author":"Athale","year":"2002","journal-title":"J Clin Oncol"},{"key":"R25-1-20210130","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/cncr.25574","article-title":". Subconjunctival carboplatin and systemic topotecan treatment in preclinical models of retinoblastoma.","volume":"117","author":"Nemeth","year":"2011","journal-title":"Cancer"},{"key":"R26-1-20210130","doi-asserted-by":"crossref","first-page":"5663","DOI":"10.1002\/cncr.27563","article-title":". Topotecan and vincristine combination is effective against advanced bilateral intraocular retinoblastoma and has manageable toxicity.","volume":"118","author":"Qaddoumi","year":"2012","journal-title":"Cancer"},{"key":"R27-1-20210130","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1158\/1078-0432.CCR-07-1243","article-title":". Using pharmacokinetic and pharmacodynamic modeling and simulation to evaluate importance of schedule in topotecan therapy for pediatric neuroblastoma.","volume":"14","author":"Panetta","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R28-1-20210130","first-page":"633","article-title":". A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors.","volume":"9","author":"Santana","year":"2003","journal-title":"Clin Cancer Res"},{"key":"R29-1-20210130","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/pbc.24356","article-title":". Intra-arterial chemotherapy is more effective than sequential periocular and intravenous chemotherapy as salvage treatment for relapsed retinoblastoma.","volume":"60","author":"Schaiquevich","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"R30-1-20210130","doi-asserted-by":"crossref","first-page":"e72441","DOI":"10.1371\/journal.pone.0072441","article-title":". Carboplatin - topotecan ophthalmic artery chemosurgery for intraocular retinoblastoma.","volume":"8","author":"Francis","year":"2013","journal-title":"PLoS One"},{"key":"R31-1-20210130","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1001\/archophthalmol.2011.5","article-title":". Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience.","volume":"129","author":"Gobin","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"R32-1-20210130","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1167\/iovs.12-9501","article-title":". Pharmacokinetic analysis of melphalan after superselective ophthalmic artery infusion in preclinical models and retinoblastoma patients.","volume":"53","author":"Schaiquevich","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R33-1-20210130","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1158\/0008-5472.CAN-11-0058","article-title":". Targeting the p53 pathway in retinoblastoma with subconjunctival Nutlin-3a.","volume":"71","author":"Brennan","year":"2011","journal-title":"Cancer Res"},{"key":"R34-1-20210130","first-page":"497","article-title":". Topotecan hydrochloride effects on retinal vessels in newborn rats.","volume":"27","author":"Pescosolido","year":"2012","journal-title":"Histol Histopathol"},{"key":"R35-1-20210130","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/02713683.2010.510943","article-title":"Camptothecin induces apoptosis of human retinoblastoma cells via activation of FOXO1.","volume":"36","author":"Han","year":"2011","journal-title":"Curr Eye Res"},{"key":"R36-1-20210130","first-page":"1300","article-title":". Induction of apoptosis in human retinoblastoma cells by topoisomerase inhibitors.","volume":"39","author":"Giuliano","year":"1998","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R37-1-20210130","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.exer.2013.10.009","article-title":". In vitro moxifloxacin drug interaction with chemotherapeutics: implications for retinoblastoma management.","volume":"118","author":"Barot","year":"2014","journal-title":"Exp Eye Res"},{"key":"R38-1-20210130","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/pbc.22504","article-title":". Intensive multimodality therapy for patients with stage 4a metastatic retinoblastoma.","volume":"55","author":"Dunkel","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"R39-1-20210130","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/archopht.1996.01100140590011","article-title":". Penetration of chemotherapy into vitreous is increased by cryotherapy and cyclosporine in rabbits.","volume":"114","author":"Wilson","year":"1996","journal-title":"Arch Ophthalmol"},{"key":"R41-1-20210130","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1001\/archopht.116.9.1209","article-title":". Intraocular concentrations of chemotherapeutic agents after systemic or local administration.","volume":"116","author":"Mendelsohn","year":"1998","journal-title":"Arch Ophthalmol"},{"key":"R42-1-20210130","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1167\/iovs.06-1152","article-title":". Topotecan vitreous levels after periocular or intravenous delivery in rabbits: an alternative for retinoblastoma chemotherapy.","volume":"48","author":"Carcaboso","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R43-1-20210130","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1167\/iovs.08-2737","article-title":". A phase I study of periocular topotecan in children with intraocular retinoblastoma.","volume":"50","author":"Chantada","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R44-1-20210130","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1167\/iovs.06-0030","article-title":". Delivery from episcleral exoplants.","volume":"47","author":"Pontes de Carvalho","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R45-1-20210130","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1167\/iovs.09-4050","article-title":". Episcleral implants for topotecan delivery to the posterior segment of the eye.","volume":"51","author":"Carcaboso","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R46-1-20210130","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1167\/iovs.07-0653","article-title":". Subconjunctival topotecan in fibrin sealant in the treatment of transgenic murine retinoblastoma.","volume":"49","author":"Tsui","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R47-1-20210130","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.ophtha.2004.11.060","article-title":". Subconjunctival carboplatin in fibrin sealant in the treatment of transgenic murine retinoblastoma.","volume":"112","author":"Van Quill","year":"2005","journal-title":"Ophthalmology"},{"key":"R48-1-20210130","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s00268-009-0252-7","article-title":"Fibrin sealant: past, present, and future: a brief review.","volume":"34","author":"Spotnitz","year":"2010","journal-title":"World J Surg"},{"key":"R49-1-20210130","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1001\/archophthalmol.2011.130","article-title":". Periocular topotecan for intraocular retinoblastoma.","volume":"129","author":"Mallipatna","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"R50-1-20210130","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jcjo.2013.05.018","article-title":". No ocular motility complications after subtenon topotecan with fibrin sealant for retinoblastoma.","volume":"48","author":"Yousef","year":"2013","journal-title":"Can J Ophthalmol"},{"key":"R51-1-20210130","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1136\/bjophthalmol-2011-301450","article-title":". Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications.","volume":"96","author":"Munier","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"R52-1-20210130","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1167\/iovs.10-5392","article-title":". Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications.","volume":"51","author":"Edelhauser","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R53-1-20210130","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.exer.2010.03.009","article-title":". Pharmacokinetic analysis of topotecan after intra-vitreal injection. Implications for retinoblastoma treatment.","volume":"91","author":"Buitrago","year":"2010","journal-title":"Exp Eye Res"},{"key":"R54-1-20210130","doi-asserted-by":"crossref","first-page":"318","DOI":"10.5507\/bp.2011.068","article-title":". Topotecan vitreous and plasma levels and retinal toxicity after transcorneal intravitreal delivery in healthy albino rabbits: alternative retinoblastoma treatment.","volume":"156","author":"Darsova","year":"2012","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"R55-1-20210130","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.exer.2013.01.002","article-title":". Ocular and systemic toxicity of intravitreal topotecan in rabbits for potential treatment of retinoblastoma.","volume":"108","author":"Buitrago","year":"2013","journal-title":"Exp Eye Res"},{"key":"R56-1-20210130","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ejpb.2011.02.012","article-title":". Development of topotecan loaded lipid nanoparticles for chemical stabilization and prolonged release.","volume":"79","author":"Souza","year":"2011","journal-title":"Eur J Pharm Biopharm"},{"key":"R57-1-20210130","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ijpharm.2012.04.056","article-title":". Multifunctionalized mesoporous silica nanoparticles for the in vitro treatment of retinoblastoma: drug delivery, one and two-photon photodynamic therapy.","volume":"432","author":"Gary-Bobo","year":"2012","journal-title":"Int J Pharm"},{"key":"R58-1-20210130","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/IAE.0b013e31821e9f8a","article-title":". Pharmacokinetic analysis of topotecan after superselective ophthalmic artery infusion and periocular administration in a porcine model.","volume":"32","author":"Schaiquevich","year":"2012","journal-title":"Retina"},{"key":"R59-1-20210130","doi-asserted-by":"crossref","first-page":"e84247","DOI":"10.1371\/journal.pone.0084247","article-title":". Electroretinogram monitoring of dose-dependent toxicity after ophthalmic artery chemosurgery in retinoblastoma eyes: six year review.","volume":"9","author":"Francis","year":"2014","journal-title":"PLoS One"},{"key":"R60-1-20210130","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/jamaophthalmol.2013.2065","article-title":". Superselective intraophthalmic artery chemotherapy in a nonhuman primate model: histopathologic findings.","volume":"131","author":"Tse","year":"2013","journal-title":"JAMA Ophthalmol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000000253","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T23:54:04Z","timestamp":1717199644000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006982-201409000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":57,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000000253","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]}}}